Partnering with pharmacists in the prevention and control of chronic diseases by National Center for Chronic Disease Prevention and Health Promotion (U.S.)
A PROGRAM GUIDE FOR PUBLIC  HEALTH
National Center for Chronic Disease Prevention and Health Promotion 
Partnering with Pharmacists in the Prevention
and Control of Chronic Diseases
1
A PRO GR AM GUIDE FOR PUBLIC HE ALT H  Par tnering with Pharmacists in the Prevention and Control of Chronic Diseases
Acknowledgments
Contributing Divisions
Division for Heart Disease and Stroke Prevention
Division of Diabetes Translation
Authors
Cynthia M. Morrison, MSPH
Denice Glover, MSW 
Siobhan M. Gilchrist, JD, MPH 
Margaret O. Casey, RN, MPH
Andrew Lanza, MPH, MSW
Rashon I. Lane, MA
Miriam Patanian, MPH
Contributors
Kristen G. Betts, RDH, BHS
Lazette Lawton, MS
Susan Ladd, MS
Mary G. George, MD, MSPH, FACS, FAHA
Sherri Yoder, PharmD, BCPS
Edward Gregg, PhD
Judy Hannan, RN, MPH
State Partners
Crystelle C. Fogle, MBA, MS, RD 
Linda Krantz, MS
Teresa M. Robinson, MBA
Adelline Ntatin, MPH, MBIM, MA
Magaly Rodriguez de Bittner, PharmD, BCPS, CDE
Philip T. Rodgers, PharmD, BCPS, FCCP
2
A PRO GR AM GUIDE FOR PUBLIC HE ALT H  Par tnering with Pharmacists in the Prevention and Control of Chronic Diseases
Executive Summary
New ways to expand team-based health care are needed to protect the health of 
Americans. Many chronic diseases, which are increasing with the aging U.S. population, 
are preventable or manageable. The role of the pharmacist has expanded beyond 
just dispensing medications and is evolving into active participation in chronic disease 
management as a part of team-based care. Programs addressing chronic diseases 
in state health departments and communities can build team relationships through 
public and private partnerships. We intend for this guide to serve as a starting point for 
Centers for Disease Control and Prevention (CDC) grantees to build these relationships 
with pharmacists and other strategic stakeholders.
The objectives of this guide are to provide the following information:
•	 		Basic	definitions	for	medication	therapy	management,	comprehensive	medication	
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Purpose of This Guide 
The National Center for Chronic Disease Prevention and Health Promotion is working 
to	transform	CDC’s	chronic	disease	activities	by	focusing	national	and	state	efforts	on	
the	‘4	Domains’	listed	below:	
1.  Environmental Approaches: Make healthy behaviors easier and more convenient 
for more people. 
2.  Health Systems: Improve delivery and use of quality clinical services to prevent 
disease, detect diseases early, and manage risk factors. 
3.  Community-Clinical Linkages: Ensure those with or at high risk for chronic 
diseases have access to quality community resources to best manage their 
conditions. 
4.  Epidemiology and Surveillance: Provide data and conduct research to inform, 
prioritize, deliver, and monitor programs and population health. 
Within	the	Community-Clinical	Linkages	domain,	CDC’s	Diabetes	Prevention	and	
Control Program (DPCP) and Heart Disease and Stroke Prevention (HDSP) Programs 
both include a focus on enhancing the role of community pharmacists in team-based 
care as outlined below: 
•	 	DPCP	Core	Diabetes	Interventions	and	Strategies:	“Expand	the	role	of	allied	health	
professionals by replicating and scaling evidence-based programs founded on the 
principles of the Asheville Project and the Diabetes 10-City Challenge.” 
•	 	HDSP	Programs	Strategies	for	States	to	Address	the	“ABCS”	of	Heart	Disease	and	
Stroke	Prevention:	“Promote	use	of	pharmacists	as	health	care	extenders	to	promote	
control of hypertension and high blood cholesterol.”
Basic Definitions
Medication Therapy Management 
As	defined	by	the	American	Pharmacists	Association,	medication	therapy	
management (MTM) is a term used to describe a broad range of health care services 
provided by pharmacists, the medication experts on the health care team. A 
consensus	definition,	adopted	by	the	pharmacy	profession	in	2004,	defines	MTM	
as a service or group of services that optimize therapeutic outcomes for individual 
patients.	Pharmacists	provide	MTM	to	help	patients	get	the	best	benefits	from	their	
medications by actively managing drug therapy and by identifying, preventing, and 
resolving medication-related problems. MTM services are independent of, but can 
occur in conjunction with, the provision of a medication or medical device.
Core Elements of a 
Medication Therapy 
Management Service Model 
(MTM) in Pharmacy Practice*
1.  Medication therapy review (MTR) is 
a systematic process of collecting 
patient-specific	information,	
assessing medication therapies 
to identify medication-related 
problems, developing a prioritized 
list of medication-related 
problems, and creating a plan to 
resolve them.
2.  Personal medication record (PMR) 
is a comprehensive record of the 
patient’s	medications	(prescription	
and nonprescription medications, 
herbal products, and other dietary 
supplements).
3.  Medication-related action 
plan (MAP) is a patient-centric 
document containing a list 
of actions for the patient to 
use in tracking progress for 
self-management.
4.  Intervention and/or referral 
includes provision of consultative 
services and interventions to 
address medication-related 
problems; when necessary, the 
pharmacist refers the patient to 
a physician or other health care 
professional.
5.  Documentation and follow-up 
include consistent documentation 
of MTM services and scheduling of 
follow-up MTM visits based on the 
patient’s	medication-related	needs	
or when the patient is transitioned 
from one care setting to another.
*  American Pharmacists Association 
and National Association of 
Chain Drug Stores Foundation. 
Medication Therapy Management 
in Pharmacy Practice: Core 
Elements of an MTM Service 
Model Version 2.0. 2008.
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Pharmacists provide MTM services in all care settings in which patients take 
medications.	Although	pharmacists	in	different	settings	may	provide	different	types	of	
services, the goal of all pharmacists providing MTM is to make sure that the medication 
is right for the patient and his or her health conditions and that the best possible 
outcomes from treatment are achieved. 
Comprehensive Medication Management
In The Patient-Centered Medical Home: Integrating Comprehensive Medication 




individually assessed to determine that each medication is appropriate for the 
patient,	effective	for	the	medical	condition,	safe	given	the	comorbidities	and	other	
medications being taken, and able to be taken by the patient as intended. Within this 
system, each medication is assessed for the medical condition or indication for which 
it is taken. To produce clinically useful data, the indication must be electronically linked 
with the product, dose, duration, manner in which the medication is taken, therapy 
goals, clinical parameters that determine progress toward these goals, and actual 
outcomes. The clinical status of the patient must be determined for each drug and 
each condition (e.g., current blood pressure level and cholesterol levels for patients 
with high blood pressure and high cholesterol). Without knowledge of the current 
clinical	status	of	a	patient,	the	indication,	appropriateness,	and	effectiveness	of	most	
medications cannot be determined.  
Comprehensive medication management includes an individualized care plan 
that achieves the intended goals of therapy with appropriate follow-up to help 
the pharmacist determine actual patient outcomes.  The pharmacist evaluates the 
outcome	parameters	against	the	patient’s	individualized	therapy	goals	and	re-
evaluates the patient to identify any new medication-related problems that might 
interfere	with	the	safe	and	effective	use	of	medications	in	the	patient’s	care	plan.	These	
follow-up	evaluations	occur	in	a	time	frame	that	is	clinically	appropriate	for	the	specific	
patient as well as his or her medical conditions and drug therapy plan. Evaluation time 
frames	vary	with	each	patient	and	are	triggered	when	major	transitions—such	as	
hospitalization—occur	or	at	the	request	of	the	patient’s	providers/prescribers.
Collaborative Drug Therapy Management 





As you seek pharmacists as 
partners, understanding their 
background may be helpful. Today, 
pharmacists graduate with a Doctor 
of Pharmacy degree, commonly 
referred	to	as	a	“PharmD.”	Some	
longer-practicing pharmacists 
may not have a PharmD but 
have a Bachelor of Science (BS) 
in pharmacy. Because the BS was 
more focused on drug distribution 
and dispensing, in 2004, the 
American Council of Pharmaceutical 
Education made the PharmD the 
required degree for accredited 
pharmacy	programs	in	an	effort	to	
provide more clinical education. 
Presently, pharmacists also have 
the opportunity to complete one 
or two years of optional residency 
training after graduation. Residency 
training can occur in hospitals, 
community pharmacies, or other 
sites and prepares the pharmacist 
for more advanced practice in 
those areas. 
Additionally, pharmacists may 
choose	to	complete	certificate	
programs focused on the 
management	of	specific	disease	
states	or	other	certifications	that	
demonstrate competency and 
expertise in a certain area. The 
Board of Pharmaceutical Specialties 
offers	certification	in	six	areas	of	
specialty in pharmacy, designated 
by credentials after the PharmD. 
Some pharmacists may seek 
credentials that cross professional 
boundaries	to	further	differentiate	
themselves, such as becoming a 
Certified	Diabetes	Educator.
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for performing patient assessments; 
ordering drug therapy-related 
laboratory tests; administering drugs; 
and selecting, initiating, monitoring, 
continuing, and adjusting drug 
regimens.” CDTM is best used when 
providing an advanced level of service 
whereby the pharmacist not only has 
access	to	a	patient’s	medical	record	but
has dedicated clinical time as well.  
Although MTM is often conducted 
through a collaborative relationship 
with patients and other health care professionals, it is already within the scope of 
pharmacy practice and does not require a formal collaborative practice agreement. 
CDTM laws vary by state, and pharmacists must comply with the requirements of the 
state in which they practice.
Team-Based Care
According	to	the	proposed	definition	from	a	working	group	of	the	Institute	of	
Medicine, team-based health care is the provision of health services to individuals, 
families, and/or their communities by at least two health providers who work 
collaboratively	with	patients	and	their	caregivers—to	the	extent	preferred	by	
each	patient—to	accomplish	shared	goals	within	and	across	settings	to	achieve	






Employers can administer insurance plans internally or hire a third-party administrator 
to provide assistance only.
Role of the Pharmacist in Team-Based Care
The role of pharmacists in providing patient care services is compatible and synergistic 
with the patient-centered medical home model and other innovative models of 
team-based care. Pharmacists extend the health care team to the local community, 
providing patients with the resources and care they need. In addition, pharmacists are 
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of medicines (prescription and over-the-counter) than any other member of the health 
care	team.	Research	shows	real	value	in	pharmacists’	management	of	diabetes	and	
heart disease. For the millions of Americans with uncontrolled diabetes, the risk for 
heart	disease,	stroke,	kidney	failure,	blindness,	and	amputation	are	significant.	Engaging	
pharmacists	as	members	of	the	health	care	system	can	significantly	improve	treatment	
of diabetes, better control high blood pressure, improve management of cholesterol, 
and reduce overall health care costs.  
Evidence to Support Maximizing Pharmacists’ 
Engagement in Team-Based Care
The booklet, Pharmacists and the Health Care Puzzle: Improving Medication Use and 
Reducing Health Care Cost, developed by the American Pharmacists Association, 
describes how pharmacists have demonstrated value and savings to the health care 
system.	It	further	explains	how	services	such	as	MTM	affect	health	outcomes	and	gives	
examples of services pharmacists provide to improve chronic care management for 
cardiovascular risk factors, such as diabetes and hypertension.
A recent report to the U.S. Surgeon General, entitled Improving Patient and Health 
System Outcomes through Advanced Pharmacy Practice, uses objective data to 
demonstrate how models of innovative care involving pharmacists can ultimately 
help alleviate demands on the health care system (e.g., access, safety, quality, cost, 
provider shortages, etc.) and improve patient outcomes. The report describes existing, 
accepted, and successful models of health care delivery and patient care using 
pharmacists as health care providers and essential members of the health care team. 
The report provides a thorough, evidence-based discussion of the comprehensive 
MTM services that pharmacists currently provide. For nearly 50 years, federal 
pharmacists have been able to practice collaboratively with physicians and other 
health care providers in expanded scopes, delivering comprehensive disease 
management, health promotion, disease prevention, MTM, and other cognitive clinical 
services. The report presents public- and private-sector models and calls for health 
leadership and policymakers to support and implement existing, evidence-based, and 
cost-effective	pharmacist-delivered	patient	care	models	as	the	demands	within	the	
nation’s	health	care	system	escalate.
One way to measure the cost-efficiencies of pharmacist-delivered CDTM is to consider 
the calculated return on investment (ROI), which reflects the value of the service based 
on the cost of delivering the service. The data collected from CDTM demonstrated 
an ROI of as high as 12:1 and an average between 3:1 and 5:1. This value is based on 
the ability of medication management services to reduce hospital admissions, use of 
unnecessary or inappropriate medications, emergency room admissions, and overall 
physician visits. 
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For example, in the Asheville Project, employees of the city of Asheville with 
conditions such as diabetes, asthma, hypertension, and high cholesterol received 
intensive	self-management	education	through	the	Mission-St.	Joseph’s	Diabetes	and	
Health Education Center. The employees teamed up with their local pharmacists, 
who ensured they were using their medications correctly. The project found that 
pharmacists improved the clinical outcomes of diabetes patients and reduced overall 
health care costs. This MTM model provided chronic care management through 
ongoing education, monitoring, follow-up, and referrals for patients with diabetes. An 
expansion of the Asheville Project to other chronic conditions demonstrated that after 
six months, 69% of participants with high cholesterol achieved their cholesterol goal 
versus 33% at baseline, and 81% of participants with hypertension reached their blood 
pressure goal versus 30% at baseline. Employers who supported these projects also 
benefited	substantially	from	increased	productivity	and	fewer	employee	sick	days.		
Pharmacist Scope of Practice Policies 
Federal and state policies have advanced the role of pharmacists in direct patient care 
through	MTM	reimbursement,	pharmacy	service	definitions,	and	advanced	pharmacy	
models to achieve optimal medication use and patient and therapeutic outcomes. 
Federal Policies 
At the federal agency level, the Indian Health Service (IHS) has been engaged in an 
advanced pharmacy practice model whereby pharmacists deliver direct patient 
care services with physician collaboration since the early 1970s. The Veterans Health 
Administration implemented a similar program in 1995 that updated the granting 
of prescribing authority for clinical pharmacy specialists. Interestingly, the basic level 
of pharmacy care that IHS provides falls under general MTM (medication review, 
counseling, and monitoring of therapeutic outcomes) that is more commonly 
seen	in	the	private	sector.	These	advanced	models	have	increasingly	diffused	into	
the private sector over the past two decades, mainly within hospitals, clinics, and 
educational facilities. 
On a federal policy level, the Medicare Prescription Drug, Improvement, and 
Modernization Act (MMA) of 2003, Public Law 108-173, was enacted to control 
health care costs and improve the quality of care. This law required Medicare Part D 
prescription	drug	plan	sponsors	to	offer	pharmacist	MTM	services	to	beneficiaries	with	
multiple chronic diseases (e.g., diabetes, hypertension). Medicare Part D plan sponsors 
are required to reimburse pharmacies for MTM services, but rates and eligibility criteria 
may vary and, in many cases, are inadequate and lack feasibility.
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State Policies
As of January 2011, 31 states have laws that allow physicians and pharmacists to 
collaborate in providing advanced services (such as those outlined in the CDTM 
definition	above)	that	could	occur	in	a	community	pharmacy	setting,	for	conditions	
such as hypertension and high cholesterol. Eleven additional states allow pharmacists 
to provide these CDTM-type services under limited conditions, such as for hospitalized 
patients only, or solely to administer vaccinations and emergency contraception. 
Several other states have since enacted laws authorizing CDTM.
Policies requiring reimbursement by insurers and Medicaid for pharmacist services are 
not widespread. As of January 2011, only three state Medicaid programs (Minnesota, 
Missouri, and Oregon) reimburse for MTM services provided by a pharmacist through 
individual, face-to-face assessment and intervention. 
Addressing Chronic Disease in Pharmacies
Medication Adherence
Medication adherence is the degree to which patients take medications as directed 
by their physician or licensed health professional. Medication non-adherence is the 
degree to which patients do not take medications as directed, which is costly and 
dangerous. One report estimated that 18% of unresolved drug-related issues involved 
medication non-adherence. Poor adherence to medications increases overall health 
care costs as patients become sicker faster and require more costly interventions. 
Data show that as many as half of all patients do not adhere to their prescription-
medication regimens, and the result is more than $100 billion spent each year on 
avoidable	hospitalizations.	Non-adherence	to	medication	regimens	also	affects	
quality and length of life; for example, one study estimated that better adherence 
to antihypertensive treatment alone could prevent 89,000 premature deaths in the 




The Diabetes Prevention Program study has shown that a chronic disease such as 
diabetes	can	be	prevented	or	managed	with	appropriate	changes	or	modifications	
to	a	person’s	lifestyle.	For	example,	the	risk	of	developing	diabetes	and	heart	disease	
may be reduced with good nutrition, weight loss, and regular physical activity; 
once diagnosed, these conditions can be managed with medication and behavior 
modification.	A	pharmacist	in	a	community	setting	(e.g.,	the	local	drug	store)	should	
consider the need for an appropriate counseling area for privacy, additional personnel 
Poor adherence to 
medications increases 
overall health care 
costs as patients 
become sicker faster 
and require more 
costly interventions.
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to assist with dispensary and other customer needs, time to provide counseling, 
professional training, and employer support.
State Health Department MTM Project Examples
Additional information for each example is provided in Appendix A.
•	 	The	Maryland	P3 Program (Patients, Pharmacists, Partnerships)TM is an example of 
comprehensive medication management that improves chronic disease-related 
health outcomes. The Maryland P3 ProgramTM uses trained pharmacists to assist 
patients with proper use of medications, diagnostic testing, counseling, and overall 
disease	management.	Pharmacists	work	in	collaboration	with	patients’	health	care	
providers to improve medication adherence and clinical and economic outcomes. 
The program currently works with self-insured employers.
 Program Contact: Adelline Ntatin, antatin@dhmh.state.md.us
•	 	The	Montana	Pharmacist	Blood	Pressure	Management	Program	targets	state	of	
Montana employees, spouses, and retirees who are active health plan members. 
Members	are	offered	face-to-face	counseling	with	a	pharmacist	and	provided	
blood pressure resources.
 Program Contact: Crystelle Fogle, cfogle@mt.gov
•	 	The	South	Carolina	Stroke	Belt	Project	replicates	the	Asheville	Model	in	counties	
with high rates of stroke mortality. Employees with chronic health problems, such as 
diabetes, hypertension, high cholesterol, and asthma, receive face-to-face coaching 
by a care manager who may be a community pharmacist or nurse educator.
 Program Contact: Joy Brooks, brooksjf@dhec.sc.gov
Working with Pharmacists to Build Chronic Disease 
MTM Programs
Planning Your Project
There are many ways chronic disease prevention and control programs can work 
with	and	support	pharmacists	in	their	efforts	to	improve	patient	outcomes	for	heart	
disease and diabetes. Below are some suggestions for how you might get started in 
partnering with the pharmacist community.
1.  Partner with an organization or group that understands this area well. First, 
look within your state health department to determine if another program is 
conducting a similar project. Some communicable disease, immunization, or 
maternal-child health programs already may be engaged with pharmacists. It 
might be more appropriate to add a focus area to an existing project rather than 
develop a new one. An ideal partner in any pharmacist-based intervention is the 
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state Medicaid program. This program works to reduce costs and improve access 
and delivery of care, and pharmacist-based programs have been shown to do that.  
When looking for external partners, consider a college or school of pharmacy. 
Management of chronic disease is an area of interest for many schools, so they may 
be	able	to	offer	a	great	deal	of	assistance.	Another	potential	partner	is	the	state 
pharmacy association. These groups work to improve quality of care, promote 
medication adherence, and enhance patient safety.   
Because	resources	and	financial	support	are	often	a	barrier	to	successful	program	
implementation, engaging the business community in your state is critical. For 
example, the Maryland P3 ProgramTM has shown that partnership with the Mid-
Atlantic and the Virginia Business Groups on Health (representing self-insured 
companies	in	the	region)	is	an	important	component	of	the	program’s	success.	For	
more information on what business health coalitions exist in your state, visit the 
National Business Coalition on Health.
  It is important to work with self-insured employers in your region because at 
this time, they are the leading model for supporting and sustaining the work 
of pharmacists in helping patients achieve blood pressure, cholesterol, and A1c 
management, thereby improving outcomes for heart disease and diabetes. 
2.   Learn	what	pharmacists	can	and	cannot	do	in	your	state—what	is	their	scope	of	
practice? The Council on Credentialing in Pharmacy provides an overview of the 
topic in Scope of Contemporary Pharmacy Practice: Roles, Responsibilities, and 
Functions of Pharmacists and Pharmacy Technicians. This resource details the 
types of practices open to pharmacists and pharmacy technicians and describes 
the scope of each. 
 Before beginning a pharmacy-related intervention, be sure to know and understand 
the regulations for the pharmacy scope of practice within your state. This 
information is usually available from the state Board of Pharmacy. The regulations 
tend to be lengthy, and each state may limit the scope of pharmacy services by 
either	commission	or	omission.	MTM	as	defined	by	the	Model Pharmacy Act and 
the MMA Act of 2003 does not require a collaborative practice agreement. In 
addition, pharmacists may adjust or modify drug therapy pursuant to verbal orders 
from the prescribing health care provider.
3.  Explore model programs including those listed above and, together with partners, 
decide	which	model	will	work	best	for	the	program.	A	pilot	project	in	a	specific	
region	or	with	a	specific	large	employer	may	be	an	option	to	consider.	Be	sure	to	
build in a rigorous evaluation for the project at the beginning of the planning stage. 
Demonstrating	effectiveness	will	help	scale	up	and	spread	the	initiative	to	other	
regions or employers over time. Aggregate, rather than individual, health outcomes 
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are more easily collected. Additionally, project costs and return on investment 
should be included as a part of the evaluation. Issues for all parties to explore when 
choosing an intervention include:
a.  Recruiting and engaging participants: Determine how to select pharmacists 
for the project and how to recruit employers.
b.  Informing and training pharmacists: Determine what curriculum will be used, 
who will provide the training, where and how the training will be conducted, and 
who will pay for the training.
c.  Reimbursement: Determine how pharmacists will be paid for their services. Is 
there a role for health plans or other payers in the project? Will a session with the 
pharmacist	be	a	covered	benefit?	Will	you	work	with	community	health	centers	
where the pharmacist is a salaried employee with expanded duties? 
4.  Focus on	policy	and/or	systems	changes	to	support	the	program’s	sustainability.	
Look for opportunities to influence or change systems or support policies as you 
move ahead with program development:
	 a.	 	Does	the	pharmacist	scope	of	practice	within	the	state	need	to	be	clarified	to	
facilitate provision of chronic disease patient care services or work as part of the 
health care team?
b.  Can community health centers ensure that the employed pharmacists provide 
MTM or more advanced chronic disease management services for patients?
	 c.	 	Can	these	services	become	a	routine	part	of	the	health	benefits	provided	by	
health plans or large self-insured employers in the state?
5.  Design your program with your partners. Research shows that in various sectors, 
pharmacists are already integrated into primary patient care as health care 
providers. Pharmacists may be very interested in helping state and community-
based programs achieve blood pressure control and cholesterol management for 
participants, thereby improving outcomes for heart disease and diabetes. The goal 
for expanding or introducing MTM services in your state should be developing 
a program that is achievable, scalable, and sustainable. The science of program 
development and collaboration with the right partners can increase your success. 
  The following resources may be useful in helping you and your partners plan and 
evaluate your program and its success. 
	 •	 	The State Program Evaluation Guides are a series of technical assistance tools 
developed by the CDC Division for Heart Disease and Stroke Prevention for 
use by state HDSP programs. The guides clarify approaches to and methods of 
evaluation,	provide	examples	specific	to	the	scope	and	purpose	of	state	HDSP	
programs, and recommend resources for additional reading.
12
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	 •	 	The	Community Tool Box is a global resource for free information on essential 
skills	for	building	healthy	communities.	It	offers	more	than	7,000	pages	of	
practical guidance in creating change and improvement.
	 •	  Redesigning the Health Care Team: Diabetes Prevention and Lifelong 
Management from the National Diabetes Education Program describes six steps 
to building a health care team that includes pharmacists.
	 •	 	CDC’s	Framework for Program Evaluation provides a systematic way to 
approach and answer evaluation questions using a set of 6 steps and 4 standards.
Choosing the Right Partners 
Patients (includes participants and employees): Individuals whose chronic 
diseases	require	a	significant	amount	of	self-management,	such	as	diabetes	or	high	
blood pressure, need to understand how pharmacists can assist them in managing 
their conditions through coaching and MTM. For many patients, pharmacists are 
the easiest health care professionals to access. The opportunities to interface with 
community	pharmacists	are	plentiful	for	most	Americans.	The	average	adult	fills	about	
12	prescriptions,	new	and	refills,	each	year;	after	65	years	of	age,	he	or	she	fills	more	
than 30 prescriptions annually. 




of Health and Mental Hygiene, the University of Maryland School of Pharmacy, the 
Mid-Atlantic and Virginia Business Groups on Health, the Maryland Pharmacists 
Association, and the Maryland General Assembly. Throughout the nation, these types 
of collaborations and partnerships vary, but there appears to be a trend in which the 
pharmacist’s	role	is	expanding	from	drug	dispenser	to	medication	therapy	manager	
and chronic disease coach. Data indicate that the average person with chronic disease 
is taking his or her medication 60%–70% of the time. In a coordinated collaborative 
approach with pharmacists and physicians, many believe that this percentage can 
increase to about 90%. 
When beginning this work, be aware of the various sectors within the pharmacist 
“world.”	To	help	with	orientation	to	these	different	types	of	pharmacists	and	learn	about	
their respective roles, see Appendix B for a list of national organizations that represent 
various pharmacist sectors at the state and local levels. Included in this list are links to 
the	organizations’	websites,	which	provide	more	information	about	different	types	of	
pharmacists, their missions, and various perspectives within the health care arena. 
As part of the interdisciplinary team approach to care promoted by the patient- 
centered medical home model, other providers also are essential partners in preventing 
The average adult fills 
about 12 prescriptions, 
new and refills, each year; 
after 65 years of age, he 
or she fills more than 30 
prescriptions annually.
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and managing chronic diseases. The key roles are that of the physician as primary care 
provider and the pharmacist as medication therapy manager and chronic disease coach. 
Payers (includes employers and health plans): Until pharmacist-administered patient 
care	services	become	a	covered	benefit,	self-insured	companies	and	employers	who	
participate in local or regional business coalitions on health will be the primary groups 
currently paying for this service. In some cases, these groups also deliver services to their 
employees. Self-insured employers/companies are particularly interested and positioned 
to work with pharmacists because these employers assume much of the health risk of 
their	employees	and	other	beneficiaries.	
Similarly,	health	plans	are	key	stakeholders	as	they	serve	as	pharmacy	benefits	
managers or third-party administrators for self-insured companies. From its inception, 
the Asheville Project had a strong business case associated with the use of community 
pharmacists as chronic disease coaches. As the Diabetes Ten City Challenge has 
shown, pharmacists increase delivery of critical control measures such as A1c tests, 
eye	and	foot	exams,	flu	shots,	and	lipid	measurements;	significantly	improve	patient	
satisfaction; and reduce health care costs overall. Members of numerous business 
health coalitions (e.g., Mid-Atlantic, Midwest, Pittsburgh) are committed to the support 
of this work, and in many cases, the worksite serves as the main location where 
services are delivered. For a full listing of business health coalitions throughout the 
United States, visit the National Business Coalition on Health.
Self-insured employers/
companies are particularly 
interested and positioned 
to work with pharmacists 
because these employers 
assume much of the 
health risk of their 
employees and other 
beneficiaries. 
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APPENDIX A
Summary of Three State Health Departments’ Work with Pharmacists
Program Maryland P3 Program (Patients, 
Pharmacists, Partnerships)TM
Montana Pharmacist Blood 
Pressure Management Program
South Carolina Stroke Belt 
Project
Scope of the 
Practice 
By statute, Maryland authorizes 
a licensed physician and 
pharmacist to enter into a written 
physician-pharmacist agreement 
(CPA)	that	specifies	the	disease	
states and treatment protocols 
the pharmacist may use to 
provide patient drug therapy 
management (MTM).
Pursuant to Mont. Code Ann. 
§37-7-101, the scope of pharmacy 
practice in Montana through a 
written collaborative pharmacy 
practice agreement with 
one or more providers allows 
pharmacists to initiate, monitor, 
and modify drug therapy; 
administer vaccines; and provide 
patient	care	as	defined	by	
protocol.
South Carolina Code of Laws 
§40-43-10	states	“the	practice	of	
pharmacy shall center around 
the provision of pharmacy care 
services and assisting the patient 
to achieve optimal therapeutic 
outcomes.”
Partners University of Maryland School of 
Pharmacy, business community, 
local pharmacies, Maryland 
Pharmacists Association, and 
Mid-Atlantic and Virginia Business 
Groups on Health.
State of Montana Health Care 
and	Benefits	Division,	University	
of Montana Skaggs School of 
Pharmacy, Montana Association 
of Health Care Purchasers, It 
Starts	With	Me	(ISWM)—health	
screening vendor for state of 
Montana.
Municipal Association of 
South Carolina, South Carolina 
Pharmacy Association, 
pharmaceutical representatives, 
South Carolina Hospital 
Association, South Carolina 
Public Health Regions, South 
Carolina Department of Health 
and	Environmental	Control’s	
Bureau of Community Health 




Self-insured businesses; also 
looking for third-party payers, 
Medicaid, and state employees. 
Pharmacists are given a one-time 







at the University of Maryland 








consisting of educational 
materials on blood pressure 
management/lifestyle, a pillbox, 






vendor who customizes lab 







management and technical 
support to administer project. 
•			Collaborate,	develop,	and	




Participants receive reduction or 
elimination of co-payments on 
medication. There is no cost to 
participants.
There is no cost to participants. Participants receive waived 
medication co-payments, 
waived laboratory co-pays, and 
free care management. 
There is no cost to participants.
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Program Maryland P3 Program (Patients, 
Pharmacists, Partnerships)TM
Montana Pharmacist Blood 
Pressure Management Program






The CPA covers medication 
therapy management (MTM), 
diagnostic testing, counseling, 
and overall disease management. 
After entering into a CPA, a 
licensed pharmacist with a 
PharmD or equivalent training 
may provide MTM to an individual 
patient	as	specified	in	a	therapy	
management contract.
Pharmacists currently are not 





The pharmacist communicates 
verbally or in writing to the 
primary care provider and  
health care team. In addition, 
pharmacists document care notes 
in a Health Information Portability 
and Accountability Act–compliant 
web-based documentation 
system. 
The pharmacist communicates 
in writing to the primary care 
provider after each interaction 
with the participant.
The pharmacist/care manager 
communicates verbally or in 
writing to the primary care 
provider and health care 
team. The care manager 
documents care notes in a 
Health Information Portability 
and Accountability Act–






reimbursement, which prevents 
program expansion into the 
larger communities.
•			Most	self-insured	employers	are	









employee data, such as 









are national in scope and 
require the program to be 
offered	to	other	out-of-state	
locations.
Outcomes The core success of the Maryland 
P3	Program™	is	the	patient’s	
improved health and clinical 
outcomes through better 
self-management and reduced 
overall costs of health care. The 
program has shown cost savings 
of $918 per employee annually, 
a reduction in absenteeism, and 
employee savings of $400–$600 
per year on average through 
incentives. 
Less than one year in 
implementation.
Less than one year in 
implementation.
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APPENDIX B
National Organizations Representing Various Pharmacist Sectors at the 
State and Local Levels
Academy of Managed Care Pharmacy (AMCP) is a national professional association 
of pharmacists and other health care practitioners who serve society by the 
application of sound medication management principles and strategies to improve 
health	care	for	all.	The	Academy’s	more	than	6,000	members	develop	and	provide	
a	diversified	range	of	clinical,	educational,	and	business	management	services	and	
strategies on behalf of the more than 200 million Americans covered by a managed 
care	pharmacy	benefit.	The	Academy	observed	its	20th	anniversary	in	2009.	
American Association of Colleges of Pharmacy (AACP) is a national organization 
representing the interests of pharmacy education and educators. Comprising 120 
accredited colleges and schools of pharmacy, including more than 6,096 faculty, 
54,700 students enrolled in professional programs, and 5,400 individuals pursuing 
graduate study, AACP is committed to excellence in pharmacy education. 
American College of Clinical Pharmacy (ACCP) is	a	professional	and	scientific	
society that provides leadership, education, advocacy, and resources enabling clinical 
pharmacists	to	achieve	excellence	in	practice	and	research.	ACCP’s	membership	is	
composed of practitioners, scientists, educators, administrators, students, residents, 
fellows, and others committed to excellence in clinical pharmacy and patient 
pharmacotherapy.
American Pharmacists Association (APhA), founded in 1852 as the American 
Pharmaceutical Association, represents more than 62,000 practicing pharmacists, 
pharmaceutical scientists, student pharmacists, pharmacy technicians, and others 
interested in advancing the profession. APhA, dedicated to helping all pharmacists 
improve	medication	use	and	advance	patient	care,	is	the	first-established	and	largest	
association of pharmacists in the United States. APhA members provide care in all 
practice settings, including community pharmacies, health systems, long-term care 
facilities, managed care organizations, hospice settings, and the uniformed services.
American Pharmacists Association (APhA) Foundation is	a	not-for-profit	501(c)
(3) organization headquartered in Washington, DC, and is affiliated with APhA, the 
oldest and largest national professional society of pharmacists in the United States. 
The APhA Foundation looks to create a new medication use system in which patients, 
pharmacists, physicians, and other health care professionals collaborate to dramatically 
improve	the	cost-effectiveness	and	quality	of	consumer	health	outcomes.	The	mission	
of	the	APhA	Foundation	is	to	optimize	the	role	of	pharmacists	in	improving	people’s	
health. The APhA Foundation will accomplish this through research, recognition, and 
resources. 
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American Society of Health-System Pharmacists (ASHP) believes that the mission 
of pharmacists is to help people make the best use of medications. The mission of 
ASHP is to advance and support the professional practice of pharmacists in hospitals 
and health systems and serve as their collective voice on issues related to medication 
use and public health.
National Alliance of State Pharmacy Associations (NASPA) promotes leadership, 
sharing, learning, and policy exchange among pharmacy leaders nationwide and 
provides education and advocacy to support pharmacists, patients, and communities 
working together to improve public health. NASPA was founded in 1927 as the 
National Council of State Pharmacy Association Executives.
National Community Pharmacists Association (NCPA) represents	America’s	
community pharmacists, including the owners of more than 23,000 independent 
community pharmacies, pharmacy franchises, and chains. Together, they represent 
an $93 billion health care marketplace, employ more than 62,400 pharmacists, and 
dispense more than 40% of all retail prescriptions. 
U.S. Public Health Service (PHS) Pharmacist Professional Advisory Committee 
(Pharm PAC) provides advice and consultation to the U.S. Surgeon General and 
Pharmacy Chief Professional Officer on issues related to the professional practice of 
pharmacy and the personnel activities of the more than 200 Civil Service and more 
than 1,000 Commissioned Corps pharmacists. Pharmacists have played a vital role in 
the PHS during the last 100 years. Although most pharmacists have been clinicians, 
many also have served in regulatory, administrative, or research roles.
For more information please contact Centers for Disease Control and Prevention 
1600 Clifton Road NE, Atlanta, GA 30333 
Telephone: 1-800-CDC-INFO (232-4636)/TTY: 1-888-232-6348 
E-mail: cdcinfo@cdc.gov Web: www.cdc.gov
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